Welcome to kongre.net

RT

SummitIn personPast event

8th RAS-Targeted Drug Development Summit

Hosted by Hanson Wade

8 – 10 September 2026
The Colonnade Hotel, Boston, United States of America
Health SciencesPharmacy & Pharmaceutical Sciences

Let others know you'll be there. This does not register you for the event.

Welcome to kongre.net

Welcome to kongre.net

Official website

Programme

Published

37 sessions across 3 days

33 speakers

Browse programme

Registration

Event has ended

Registration is handled by the organiser

Fees are listed on this page

View registration details

Key facts

8th RAS-Targeted Drug Development Summit is a summit held 8 – 10 September 2026 in The Colonnade Hotel, Boston, United States of America, organised by Hanson Wade.

Dates:: 8 – 10 September 2026
Format:: In person
Venue:: The Colonnade Hotel, Boston, United States of America
Subjects:: Pharmacy & Pharmaceutical Sciences
Organiser:: Hanson Wade
Official website:: ras-drugdevelopment.com

The 8th RAS-Targeted Drug Development Summit is an industry-focused forum dedicated exclusively to translating RAS-targeted therapies from early discovery through clinical development. Organized by Hanson Wade, the event takes place in Boston, MA from September 8 to 10, 2026. It gathers biopharma and academic leaders to discuss next-generation inhibitors, pan-RAS strategies, novel modalities, overcoming resistance, and designing smarter combination regimens across RAS-driven tumors.

Programme highlights

View full programme

Tue, 8 Sept 2026Chair’s Opening RemarksPlenary11 sessions this day
Wed, 9 Sept 2026Chair’s Opening RemarksPlenary14 sessions this day
Thu, 10 Sept 2026Chair’s Opening RemarksPlenary12 sessions this day

Speakers

View all 33 speakers

Tony Tran
Kura Oncology
Translational to Phase 1 Clinical Data for Darlifarnib + Adagrasib in Advanced KRAS G12C Solid Tumors: Results from FIT-001
Jeffrey Rothman
Oncogenuity Inc.
Achieving Allele Specific KRAS G12D Suppression By Obstructing Oncogene Transcription
Michael Hamilton
Vividion Therapeutics
Disruption of the RAS-PI3Kα Interaction Provides Enhanced Efficacy in Combination Mutant KRAS Targeting Therapies
Matthew Farren
Incyte Corporation
Expanding Patient Reach: Developing Novel INCB161734 (KRAS G12D Inhibitors) Combinations That Work Across Heterogeneous Tumors +1 more
Luke Pase
Anocca AB
Panel Discussion: Setting the Boundaries of What’s Clinically Achievable in RAS Therapy Defining the Realistic Therapeutic Window for Next-Generation Strategies +1 more
Andrew Stephen
NCI, RAS Initiative
From RAS Biochemistry to Drug Design: How Mutant Cycling & GTP Thresholds Inform Next-Generation RAS Inhibitors
Ivana Sullivan
Amgen Inc.
Advancing First Line Care for KRAS G12C positive & PD L1 negative NSCLC: Optimizing Targeted Therapy + Chemotherapy for a High-Unmet- Need Population
Jonathan Pachter
Verastem, inc
Mechanistically Differentiated KRAS G12D Inhibition: Advancing Novel Combination Strategies to Enhance Durability & Overcome Resistance

Venue & travel The Colonnade HotelBoston, United States of AmericaVenue details About the organiser Hanson Wade4 more events from this organiserOrganiser profile Who is going? See who attended this eventSee who is going

Organiser and contact

Host organisation

Hanson Wade 4 more events from Hanson Wade

Contact

Event secretary:: Anna Westgate-Maher
Email:: [email protected]

Advertisement

Related events